Algert Global LLC Bridge Bio Pharma, Inc. Transaction History

Algert Global LLC

$4.25 Billion
Q4 2024

A detailed history of Algert Global LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Algert Global LLC holds 23,600 shares of BBIO stock, worth $796,500. This represents 0.02% of its overall portfolio holdings.

Number of Shares

23,600

Previous 136,447 82.7%

Holding current value

$796,500

Previous $3.47 Million 81.35%

% of portfolio

0.02%

Previous 0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$22.35 - $29.5 $2.52 Million - $3.33 Million	-112,847 Reduced 82.7%	23,600 $648,000
Q3 2024 Nov 12, 2024	BUY	$23.91 - $31.3 $1.93 Million - $2.52 Million	80,599 Added 144.32%	136,447 $3.47 Million
Q2 2024 Aug 14, 2024	SELL	$23.0 - $31.04 $771,834 - $1.04 Million	-33,558 Reduced 37.53%	55,848 $1.42 Million
Q1 2024 May 14, 2024	BUY	$27.35 - $40.45 $50,050 - $74,023	1,830 Added 2.09%	89,406 $2.76 Million
Q4 2023 Feb 14, 2024	BUY	$24.02 - $43.89 $528,728 - $966,106	22,012 Added 33.57%	87,576 $3.54 Million
Q3 2023 Nov 13, 2023	BUY	$16.89 - $35.01 $433,735 - $899,056	25,680 Added 64.39%	65,564 $1.73 Million
Q2 2023 Aug 14, 2023	SELL	$13.29 - $18.01 $32,294 - $43,764	-2,430 Reduced 5.74%	39,884 $686,000
Q1 2023 May 12, 2023	SELL	$7.17 - $18.55 $222,313 - $575,161	-31,006 Reduced 42.29%	42,314 $702,000
Q4 2022 Feb 13, 2023	BUY	$6.74 - $11.52 $494,176 - $844,646	73,320 New	73,320 $559,000
Q2 2022 Aug 15, 2022	SELL	$5.21 - $12.14 $8,596 - $20,031	-1,650 Reduced 4.12%	38,430 $349,000
Q1 2022 May 16, 2022	BUY	$7.34 - $17.16 $294,187 - $687,772	40,080 New	40,080 $407,000

Others Institutions Holding BBIO

# of Institutions

321

Shares Held

176M

Call Options Held

13M

Put Options Held

2.48M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $5B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Bridge Bio Pharma, Inc. Transaction History